Company profile: Retrophin
1.1 - Company Overview
Company description
- Provider of therapies and programs for rare diseases, including FILSPARI (sparsentan) for adults with IgA nephropathy; a late-stage therapy for focal segmental glomerulosclerosis; a potential disease-modifying therapy for classical homocystinuria; preclinical Alagille syndrome research with NIH and ALGSA; and support for newborn screening modernization and a telehealth model to improve specialist access.
Products and services
- Classical Homocystinuria Therapy: A potential disease‑modifying therapy for people with classical homocystinuria, a rare metabolic disorder, intended to impact the course of this condition
- FILSPARI (sparsentan): A treatment for adults with IgA nephropathy (sparsentan), a rare kidney disease, delivering adult‑indicated therapeutic care for this patient population
- Focal Segmental Glomerulosclerosis (FSGS) Treatment: A therapy in late‑stage clinical development for treating focal segmental glomerulosclerosis, a rare kidney disorder, evaluated in advanced trials for this condition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Retrophin
Xenetic Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drugs, cancer therapies and vaccines, centered on a DNase I oncology platform and NETs-targeting approaches for pancreatic and other solid tumors; collaborates with Volition on NETs-targeted adoptive cell therapies; holds sublicenses for PolyXen technology for blood/bleeding disorders and DNase enzyme-based cancer treatments; contracts cGMP manufacturing of recombinant Human DNase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenetic Biosciences company profile →
Athersys
HQ: United States
Website
- Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athersys company profile →
Ablynx
HQ: Belgium
Website
- Description: Provider of a proprietary Nanobody® technology platform for the discovery and development of therapeutic nanobodies—small single-domain antibody fragments—targeting serious human diseases including inflammation, haematology, oncology and pulmonary disease, with approximately 25 projects in the pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablynx company profile →
Vertex Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule drugs for serious diseases, including cystic fibrosis medicines, and research and development of therapies for sickle cell disease, type 1 diabetes, APOL1-mediated kidney disease, pain management, and beta thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vertex Pharmaceuticals company profile →
GlycoEra
HQ: Switzerland
Website
- Description: Provider of extracellular protein degraders for autoimmune diseases, leveraging its CustomGlycan platform to design bi-functional biologics that selectively degrade circulating or membrane disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. Offerings include G-LyTACs, a custom glycan engineering platform, and protein degradation therapeutics with applications in oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoEra company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Retrophin
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Retrophin
2.2 - Growth funds investing in similar companies to Retrophin
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Retrophin
4.2 - Public trading comparable groups for Retrophin
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →